- Conditions
- Solid Tumor
- Interventions
- Epacadostat, Pembrolizumab, Oxaliplatin, Leucovorin, 5-Fluorouracil, Gemcitabine, nab-Paclitaxel, Carboplatin, Paclitaxel, Pemetrexed, Cyclophosphamide, Cisplatin, Investigator's choice of platinum agent
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1585–1608
of 2,795
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Infections, Meningococcal
- Interventions
- GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix), GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix), Infanrix®, ActHIB®, Pediarix®
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Weeks to 12 Weeks
- Enrollment
- 1,558 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 50 more
- Conditions
- Leukemia
- Interventions
- cytarabine, dexamethasone, etoposide, idarubicin, ifosfamide, leucovorin calcium, mesna, pegaspargase, therapeutic hydrocortisone, thioguanine, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy, Methotrexate
- Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 20 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2006
- U.S. locations
- 30
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 23 more
- Conditions
- Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
- Interventions
- HLX22, Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine
- Drug
- Lead sponsor
- Shanghai Henlius Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 29
- States / cities
- Anaheim, California • Los Alamitos, California • Greeley, Colorado + 24 more
- Conditions
- Abscess
- Interventions
- oral trimethoprim/sulfamethoxazole, Placebo
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 90 Days to 18 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV MAT vaccine, dTpa vaccine
- Combination Product
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 9 Years to 49 Years · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 2
- States / cities
- Miami, Florida • Beaumont, Texas
- Conditions
- Type1diabetes
- Interventions
- CGMIS (Continuous Glucose Monitoring Infusion Set)
- Device
- Lead sponsor
- Pacific Diabetes Technologies
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Renton, Washington
- Conditions
- Overweight and Obesity, Metabolic Syndrome, Weight Loss
- Interventions
- Signos System, Standard Lifestyle Education
- Device · Other
- Lead sponsor
- Signos Inc
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Walnut Creek, California • North Miami, Florida + 2 more
- Conditions
- Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
- Interventions
- Mycophenolate Mofetil, Quality-of-Life Assessment, Radiation Therapy, Temozolomide
- Drug · Other · Radiation
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Lake Forest, Illinois • Warrenville, Illinois
- Conditions
- Stroke, Hypertension
- Interventions
- Educational intervention for diet and physical activity, Educational message on skin cancer awareness
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 760 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Corpus Christi, Texas
- Conditions
- Distribution of Ropivacaine in Erector Spinae Plane Block
- Interventions
- Ropivacaine, Epinephrine
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Type 2 Diabetes
- Interventions
- Placebo, Survodutide
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Paradise Valley, Arizona + 82 more
- Conditions
- Follicular Lymphoma, Endometrial Cancer
- Interventions
- Copanlisib, Ketogenic Diet
- Drug · Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alcohol Use Disorder, Alcohol Dependence, Alcoholism
- Interventions
- Ria Treatment Platform
- Combination Product
- Lead sponsor
- Ria Health
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Healthy Volunteers (Meningococcal Infection)
- Interventions
- Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine), Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®), Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine, Varicella Virus Vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 2,797 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 56 more
- Conditions
- Electronic Cigarette Use, Cigarette Use, Electronic, Tobacco Use, Tobacco Smoking
- Interventions
- Switch from UB of Combustible Cigarette to JUUL 5% Virginia Tobacco ENDS, Switch from UB of Combustible Cigarette to JUUL 3% Virginia Tobacco ENDS, Switch from UB of Combustible Cigarette to JUUL 5% Mint ENDS, Switch from UB of Combustible Cigarette to JUUL 3% Mint ENDS, Switch from UB of Combustible Cigarette to JUUL 5% Menthol ENDS, Switch from UB of Combustible Cigarette to JUUL 3% Menthol ENDS, Switch from UB of Combustible Cigarette to JUUL 5% Mango ENDS, Switch from UB of Combustible Cigarette to JUUL 3% Mango ENDS, Switch to Dual-use of JUUL 5% and UB of Combustible Cigarette, Tobacco/Nicotine Abstention, Usual Brand of cigarettes
- Other
- Lead sponsor
- Juul Labs, Inc.
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 279 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • St Louis, Missouri + 2 more
- Conditions
- Ramadan Fasting, Obesity & Overweight, Aerobic Exercise, Weight Loss
- Interventions
- Moderate-Intensity Aerobic Exercise
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 20 Years to 60 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Stroke
- Interventions
- Actuated Virtual Keyboard (AVK) system, Occupational Therapy (OT)
- Behavioral
- Lead sponsor
- North Carolina State University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Raleigh, North Carolina
- Conditions
- Smoking Cessation, Cervical Cancer, High Grade Cervical Dysplasia
- Interventions
- Smoking Cessation treatment delivered by Tobacco Free Florida Quitline, Nicotine patch, Nicotine Lozenge, Motivation and Problem Solving (MAPS) intervention
- Behavioral · Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Thymidine Kinase 2 Deficiency
- Interventions
- Observational retrospective data
- Other
- Lead sponsor
- Zogenix MDS, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Indianapolis, Indiana • Akron, Ohio + 1 more
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- Psilocybin, Trauma-focused psychotherapy, Standard psychological support
- Drug · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma
- Interventions
- GSK2636771, Pembrolizumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Dementia
- Interventions
- Care EcoSystem
- Behavioral
- Lead sponsor
- Ochsner Health System
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Tuberous Sclerosis Complex
- Interventions
- JASPER
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 12 Months to 36 Months
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California